title: Alemtuzumab more effective than interferon β-1a at 5-year follow-up of CAMMS223 clinical trial.
authors.forename: Florian
authors.initials: F
authors.lastname: Deisenhammer
authors.forename: Harald
authors.initials: H
authors.lastname: Hegen
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D016899:Interferon-beta / Q000627:therapeutic use*; D008297:Male; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000188:drug therapy* / Q000503:physiopathology*
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D016899:Interferon-beta